Core Viewpoint - Weitengkang (603676.SH) announced that its wholly-owned subsidiary, Tibet Zhongwei Chengkang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of Lidocaine and Bupivacaine Cream [1] Group 1 - The approved product, Lidocaine and Bupivacaine Cream, was developed by Zars Company and was approved by the FDA in the United States on June 29, 2006, under the brand name Pliaglis [1] - The cream contains 70mg of Lidocaine and 70mg of Bupivacaine per gram [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Tibet Zhongwei Chengkang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of Lidocaine Dincaine Cream for local anesthesia in adult skin surgeries [1] Group 1 - The approval includes a clinical trial notification for the use of the product on intact skin prior to surgical procedures [1]

Core Viewpoint - Weitengkang (603676.SH) announced that its wholly-owned subsidiary, Tibet Zhongwei Chengkang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the clinical trial of Lidocaine and Bupivacaine Cream, marking a significant step in the development of this product for local anesthesia in adult skin surgeries [1] Group 1: Clinical Trial Approval - The NMPA approved the clinical trial application for Lidocaine and Bupivacaine Cream, which was submitted on September 17, 2025, confirming compliance with drug registration requirements [1] - The cream is intended for local anesthesia on intact skin prior to adult skin surgeries [1] Group 2: Product Background - Lidocaine and Bupivacaine Cream was developed by Zars Company and received FDA approval in the United States on June 29, 2006, under the brand name Pliaglis, with a formulation containing 70mg of Lidocaine and 70mg of Bupivacaine per gram [1] - The NMPA's 31st batch of reference preparation catalog specifies that the reference preparation for this cream is the unimported original drug approved in the U.S. Orange Book and the EU, with licensed manufacturers being Taro Pharmaceuticals and Difa Cooper SPA/Galderma Laboratorium GmbH [1] - Currently, this product is not available in the domestic market [1]

Core Viewpoint - Weixingkang (603676.SH) announced that its wholly-owned subsidiary, Tibet Zhongwei Chengkang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the clinical trial of Lidocaine and Dicaine Cream, which is intended for local anesthesia in adult skin surgeries [1] Group 1 - The clinical trial application for Lidocaine and Dicaine Cream was accepted on September 17, 2025, and meets the requirements for drug registration [1] - The cream was developed by Zars Company and was approved by the FDA in the United States on June 29, 2006, under the brand name Pliaglis, containing 70mg of Lidocaine and 70mg of Dicaine per gram [1] - The NMPA's 31st batch of reference preparation directory identifies the reference preparation for Lidocaine and Dicaine Cream as the unimported original drug listed in the US Orange Book and the EU, with the license holders being Taro Pharmaceuticals and Difa Cooper SPA/Galderma Laboratorium GmbH [1] Group 2 - Currently, there are no domestic listings for this product in China [1]

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Tibet Zhongwei Chengkang, has received approval from the National Medical Products Administration for the clinical trial of Lidocaine and Bupivacaine Cream, which is a significant development for the company in expanding its product portfolio in the pharmaceutical market [1] Group 1: Product Development - The Lidocaine and Bupivacaine Cream was developed by Zars Company and received FDA approval in the United States on June 29, 2006, under the brand name Pliaglis [1] - The cream contains 70mg of Lidocaine and 70mg of Bupivacaine per gram [1] - Currently, there are no domestic listings for this product in China [1] Group 2: Regulatory Approval - The National Medical Products Administration has included the Lidocaine and Bupivacaine Cream in the 31st batch of reference preparation directory, confirming its status as a reference preparation for unimported original drugs listed in the US Orange Book and the EU [1] - The licensed manufacturers for the reference preparation are Taro Pharmaceuticals and Difa Cooper SPA/Galderma Laboratorium GmbH [1]

公司研究 证 券 研 究 报 告 卫信康（603676）2025 年三季报点评 推荐（下调） 非经事项扰动短期业绩，期待后续经营改善 目标价：15.4 元 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 1,300 | 1,222 | 1,414 | 1,659 | | 同比增速(%) | -1.7% | -6.0% | 15.8% | 17.3% | | 归母净利润(百万) | 246 | 273 | 336 | 413 | | 同比增速(%) | 15.0% | 10.7% | 23.4% | 22.9% | | 每股盈利(元) | 0.57 | 0.63 | 0.77 | 0.95 | | 市盈率(倍) | 19 | 17 | 14 | 12 | | 市净率(倍) | 3.4 | 3.0 | 2.6 | 2.2 | 资料来源：公司公告，华创证券预测 注：股价为 2025 年 11 月 21 日收盘价 化学制剂 2025 年 11 月 23 日 | | | 华创证券研究所 证券分析师：郑辰 ...

分组1 - 莱绅通灵 announced a cash dividend of 0.10 yuan per share (tax included), with the record date on November 24, 2025, and the ex-dividend date on November 25, 2025 [1] - 卫信康 declared a cash dividend of 0.147 yuan per share (tax included), with the record date on November 25, 2025, and the ex-dividend date on November 26, 2025 [1] - 宏辉果蔬 issued a cash dividend of 0.005 yuan per share (tax included), with the record date on November 24, 2025, and the ex-dividend date on November 25, 2025 [1] 分组2 - 杭叉集团 reported a cash dividend of 0.2 yuan per share (tax included), with the record date on November 25, 2025, and the ex-dividend date on November 26, 2025 [2] - 新坐标 announced a cash dividend of 0.25 yuan per share (tax included), with the record date on November 25, 2025, and the ex-dividend date on November 26, 2025 [2] - 厦门象屿 declared a cash dividend of 0.1 yuan per share (tax included), with the record date on November 24, 2025, and the ex-dividend date on November 25, 2025 [2] 分组3 - 鼎泰高科 announced a cash dividend of 4.0 yuan for every 10 shares (tax included), with the record date on November 24, 2025, and the ex-dividend date on November 25, 2025 [3] - 宝莱特 declared a cash dividend of 0.494386 yuan for every 10 shares (tax included), with the record date on November 25, 2025, and the ex-dividend date on November 26, 2025 [3] - 华明装备 issued a cash dividend of 0.1999450 yuan per share (tax included), with the record date on November 24, 2025, and the ex-dividend date on November 25, 2025 [3] 分组4 - 金岭矿业 announced a cash dividend of 0.50 yuan for every 10 shares (tax included), with the record date on November 26, 2025, and the ex-dividend date on November 27, 2025 [4]

Core Viewpoint - The company announced its profit distribution plan for the first three quarters of 2025, detailing a cash dividend of 0.147 yuan per share, which represents 29% of the net profit attributable to shareholders for the same period [2][5][9]. Distribution Plan - The distribution year is set for the first three quarters of 2025 [4]. - The distribution is applicable to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the registration date [4]. - The total number of shares eligible for distribution is 432,334,800 shares after excluding shares held in the company's repurchase account [5]. Dividend Details - The company plans to distribute a total cash dividend of 63,553,215.60 yuan (including tax) [5]. - The cash dividend distribution will not include stock dividends or capital reserve transfers [5]. - The cash dividend per share is calculated as approximately 0.1460 yuan after adjustments [7]. Taxation Information - For individual shareholders, the tax treatment varies based on the holding period of the shares, with a maximum tax rate of 20% for shares held for one month or less [9][10]. - Qualified Foreign Institutional Investors (QFIIs) will have a withholding tax of 10%, resulting in a net cash dividend of 0.1323 yuan per share [11]. - Hong Kong investors will also face a 10% withholding tax, with similar provisions for tax treaty benefits [12]. Implementation Method - Shares held in the company's repurchase account will not participate in the profit distribution [8]. - Cash dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation [7].

Core Points - The company Weixin Kang announced a cash dividend distribution plan for the first three quarters of 2025, proposing a cash dividend of 0.147 yuan per share (tax included) [2] - The record date for the dividend is set for November 25, 2025, and the ex-dividend date is November 26, 2025 [2]

Core Viewpoint - Weishinkang (603676.SH) announced a cash dividend distribution plan for the first three quarters of 2025, proposing a cash dividend of 0.147 yuan per share (tax included) to all shareholders [1] Summary by Sections Dividend Distribution - The profit distribution is based on the total share capital after deducting shares held in the company's repurchase account, resulting in a total of 432 million shares eligible for dividend distribution [1] - The total cash dividend to be distributed amounts to 63.5532 million yuan (tax included), which represents 29.00% of the net profit attributable to the parent company's shareholders for the first three quarters of 2025 [1] Key Dates - The record date for the dividend distribution is set for November 25, 2025, and the ex-dividend date is November 26, 2025 [1]